[1] Listed N. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep, 1991,40: 1-25.
[2] Zou H, Chen Y, Duan Z, et al. Protective effect of hepatitis B vaccine combined with two-dose hepatitis B immunoglobulin on infants born to HBsAg-positive mothers. PLoS One, 2011, 6: e26748.
[3] 沙庆洪. 乙型肝炎血源疫苗不同免疫剂量阻断新生儿母婴传播的效果观察. 病毒学报, 1991: 56-60.
[4] 夏国良, 龚健, 王继杰, 等. 重组乙型肝炎疫苗阻断乙型肝炎病毒母婴传播方案的保护效果评价. 中华流行病学杂志, 2003,24: 362-365.
[5] 郝红晓, 张璐, 李明慧, 等. 影响HBV母婴阻断效果的相关因素研究进展. 中华实验和临床病毒学杂志, 2015,29: 93-94.
[6] 杨翠丽, 王斯, 马文阁, 等. 不同剂量乙肝疫苗联合乙肝免疫球蛋白阻断乙肝母婴传播探讨. 河北医药, 2008,30: 1493-1494.
[7] 王建设, 朱启. 乙肝免疫球蛋白联合乙肝疫苗阻断乙型肝炎病毒母婴传播长期随访研究. 中国实用儿科杂志, 2000,15: 558-560.
[8] 刘海英, 马玉燕, 崔保霞, 等. 孕妇乙肝免疫球蛋白被动免疫阻断HBV母婴垂直传播作用机理的研究. 现代妇产科进展, 2002,11: 128-130.
[9] 邹怀宾, 陈煜, 段钟平, 等. HBeAg阳性孕妇孕晚期注射HBIG阻断HBV母婴传播研究: 全国疑难及重症肝病大会, 2011.
[10] 尹玉竹, 周瑾, 张培珍. 孕晚期注射HBIG阻断HBV母婴传播的病例对照研究. 中国优生与遗传杂志, 2013: 107-108.
[11] Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep, 2006,55: 1-33, E1-E4.
[12] Wen WH, Chen HL, Ni YH, et al. Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. Hepatology, 2011,53: 429-436.
[13] Jaffe A, Brown RJ. A review of antiviral use for the treatment of chronic hepatitis B virus infection in pregnant women. Gastroenterol Hepatol (NY), 2017,13: 154-163.
[14] 李文凡, 姜瑞, 卫峥, 等. 拉米夫定阻断慢性HBV感染孕妇母婴传播的临床效果和安全性. 肝脏, 2006,11: 106-107.
[15] Sinha S, Kumar M. Pregnancy and chronic hepatitis B virus infection. Hepatol Res, 2010,40: 31-48.
[16] 梁茜, 李倪, 孙艳艳, 等. 抗病毒药物阻断乙型肝炎母婴传播的研究进展. 天津医药, 2016,44: 381-384.
[17] Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol, 2011,55: 1215-1221.
[18] Zhang H, Pan CQ, Pang Q, et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology, 2014, 60: 468-476.
[19] Chen C, Tu X, Cheng Q, et al. Clinical observation of telbivudine's antiviral efficacy and protection against mother-to-infant transmission of chronic hepatitis B during the first trimester of pregnancy. Zhonghua Gan Zang Bing Za Zhi, 2015,23: 9-12.
[20] Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology, 2015,62: 375-386.
[21] Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med, 2016,374: 2324-2334.
[22] Celen MK, Mert D, Ay M, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol, 2013,19: 9377-9382.
[23] Hu YH, Liu M, Yi W, et al. Tenofovir rescue therapy in pregnant females with chronic hepatitis B. World J Gastroenterol, 2015,21: 2504-2509.
[24] Bzowej NH. Optimal management of the hepatitis B patient who desires pregnancy or is pregnant. Curr Hepat Rep, 2012,11: 82-89. |
